| 國立臺灣大學 |
2008 |
Gemcitabine Plus Conventional-Dose Epirubicin Versus Gemcitabine Plus Cisplatin as First-Line Chemotherapy for Stage Iiib/Iv Non-Small Cell Lung Carcinoma-a Randomized Phase Ii Trial
|
許駿; 郭頌鑫; 胡賦强; 鄭安理; 施金元; 余忠仁; 林家齊; 楊泮池; 楊志新; HSU, CHIUN; KUO, SUNG-HSIN; HU, FU-CHANG; CHENG, ANN-LII; SHIH, JIN-YUAN; YU, CHONG-JEN; LIN, CHIA-CHI; YANG, PAN-CHYR; YANG, CHIH-HSIN |
| 臺大學術典藏 |
2020-05-25T07:35:30Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C; Kuo S.-H; Hu F.-C; Cheng A.-L; Shih J.-Y; Yu C.-J; Chia-Chi Lin; Huang T.-C; Yang P.-C; Yang C.-H. |
| 臺大學術典藏 |
2020-12-02T02:34:30Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; PAN-CHYR YANG; Yang C.-H. |
| 臺大學術典藏 |
2021-02-23T08:26:37Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; SUNG-HSIN KUO; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:26Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; ANN-LII CHENG; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-06-27T07:07:53Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; CHONG-JEN YU; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2018-09-10T06:52:59Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma—A randomized phase II trial
|
Chiun Hsu and Sung-Hsin Kuo and Fu-Chang Hu and Ann-Lii Cheng and Jin-Yuan Shih and Chong-Jen Yu and Chia-Chi Lin and Tsu-Chen Huang and Pan-Chyr Yang and Chih-Hsin Yang; Chong-Jen Yu; Sung-Hsin Kuo; JIN-YUAN SHIH; ANN-LII CHENG |
| 國家衛生研究院 |
2015-11 |
Gemcitabine synergistically enhances anti-tumor effects of recombinant immunogen-based cancer immunotherapy
|
Liu, SJ;Chang, LS;Yan, WL;Yeh, YC;Leng, CH |
| 國家衛生研究院 |
1997-05 |
Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study
|
Perng, RP; Chen, YM; MingLiu, J; Tsai, CM; Lin, WC; Yang, KY; WhangPeng, J |
| 臺大學術典藏 |
2021-02-23T08:26:35Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
Yang S.-H.; Lin Z.-Z.; SUNG-HSIN KUO; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-10T03:53:07Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
SHIH-HUNG YANG; Lin Z.-Z.; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:51Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
Yang S.-H.; ZHONG-ZHE LIN; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-09-01T01:54:20Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
Yang S.-H.; Lin Z.-Z.; Kuo S.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-12T04:01:31Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
YANG SHIH-HUNG; Lin Z.-Z.; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-03-08T03:44:08Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
SHIH-HUNG YANG; Lin Z.-Z.; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:13Z |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma
|
Yang S.-H.; ZHONG-ZHE LIN; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2018-09-10T03:52:56Z |
Gemcitabine-induced acute lipodermatosclerosis-like reaction
|
Chu, C.-Y. and Yang, C.-H. and Chiu, H.-C.; HSIEN-CHING CHIU; CHIA-YU CHU |
| 國立臺灣大學 |
2001 |
Gemcitabine-Induced Acute Lipodermatosclerosis-Like Reaction
|
朱家瑜; 楊志新; 邱顯清; CHU, CHIA-YU; YANG, CHIH-HSIN; CHIU, HSIEN-CHING |
| 臺大學術典藏 |
2019-12-04T08:44:23Z |
Gemcitabine-induced acute lipodermatosclerosis-like reaction
|
Chia-Yu Chu;Yang C.-H.;Chiu H.-C.; CHIA-YU CHU; Yang C.-H.; Chiu H.-C. |
| 臺大學術典藏 |
2019-12-05T06:27:02Z |
Gemcitabine-induced acute lipodermatosclerosis-like reaction
|
Chu C.-Y.;Yang C.-H.;Hsien-Ching Chiu; Chu C.-Y.; Yang C.-H.; HSIEN-CHING CHIU |
| 臺大學術典藏 |
2020-05-26T09:27:32Z |
Gemcitabine-induced acute lipodermatosclerosis-like reaction
|
Chu C.-Y;Chih-Hsin Yang;Chiu H.-C.; Chu C.-Y; CHIH-HSIN YANG; Chiu H.-C. |
| 國立成功大學 |
2021-07-8 |
Gemcitabine-induced Gli-dependent activation of hedgehog pathway resists to the treatment of urothelial carcinoma cells
|
Chang;Yu-Hao;Tam;Hoi-Lam;Lu;Meng-Chien;Huang;Huei-Sheng |
| 臺北醫學大學 |
2005 |
Gemcitabine/Carboplatin Chemotherapy for pure small cell carcinoma of the prostate: A case report.
|
朱娟秀; Chen KC; Chiu AW; Chiang HS; Chu JS; Cheng CJ; |
| 高雄醫學大學 |
2012 |
gemcitabine在膀胱癌細胞中降解cyclin D1的機轉
|
徐偉齊;高于婷;侯自銓;蒲永孝;黃阿梅 |
| 國立交通大學 |
2014-12-08T15:39:12Z |
GEMDOCK: A generic evolutionary method for molecular docking
|
Yang, JM; Chen, CC |
